2024
Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
Elkeraie A, Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaedi A, AlSuwaida A, Arici M, Ecder T, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective. International Journal Of Nephrology And Renovascular Disease 2024, 17: 1-16. PMID: 38196830, PMCID: PMC10771977, DOI: 10.2147/ijnrd.s430532.Peer-Reviewed Original ResearchChronic kidney diseaseSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsDiabetes mellitusKidney diseaseType 2 diabetes mellitusMajor public health concernAldosterone system inhibitorsBetter clinical outcomesCause of deathPublic health concernNephrology referralCKD managementClinical outcomesSystem inhibitorsCardioprotective propertiesEarly initiationTreatment pathwaysConsensus recommendationsHigh riskPatientsBetter careHealth concernEarly detectionHypertension
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment